Rheumatology Network's Top 5: May 28, 2022


Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 28, 2022.

Promising Phase 3 Bimekizumab Data for Treatment of Psoriatic Arthritis

Two phase 3 studies, BE OPTIMAL and BE COMPLETE, evaluated bimekizumab in adults with active psoriatic arthritis who were biologic-naïve and TNF-inadequate responders.

James Woody, MD, PhD: Anti-TNF for Dupuytren’s Disease Treatment

James Woody, MD, PhD, explains the benefits of treating Dupuytren’s disease with anti-tumor necrosis factor (TNF).

Patient-Reported Outcomes: Rheumatoid Arthritis, Psoriatic Arthritis, and Myositis

Clinicians give their opinions on patient-reported outcome measures regarding both initial diagnosis and management of patients with rheumatic disease.

Severe Psoriasis Skin Involvement Positively Associated with Psoriatic Arthritis Diagnosis

Investigators conducted a meta-analysis to determine the association between psoriasis and an eventual psoriatic arthritis diagnosis.

Glucocorticoids Linked to Increase in COVID-19 Hospital Admissions in Patients with RA

COVID-19 has raised additional concerns for rheumatologists, especially regarding health care for patients with rheumatic diseases.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.